Neoadjuvant Chemotherapy and Short-term Morbidity in Patients Undergoing Mastectomy With and Without Breast Reconstruction
Nicholas B. Abt(Massachusetts Eye and Ear Infirmary), Gedge D. Rosson(Johns Hopkins University), Francis Abreu(Johns Hopkins University), Carisa M. Cooney(Johns Hopkins University), José M. Flores(Johns Hopkins University), Vered Stearns(Johns Hopkins University), Karim A. Sarhane(Johns Hopkins University), Martin A. Makary(United States Food and Drug Administration), Pablo A. Baltodano(Johns Hopkins University), Michele A. Manahan(Johns Hopkins University)
Cited by 50
Related Papers
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
|Journal of Clinical Oncology|2010|800
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
|Journal of Clinical Oncology|2014|795
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751